Removab: antibody treatment for malignant ascites

Removab (catumaxomab) is now available to treat malignant ascites due to EpCAM-positive carcinomas where standard therapy is not available or not feasible.

Catumaxomab is a hybrid rat-mouse monoclonal antibody that has binding sites for the epithelial cell adhesion molecule (EpCAM) and CD3, a component of the T cell receptor. It stimulates a range of immune responses against tumour cells.

A randomised, open-label trial compared catumaxomab (as 4 intraperitoneal infusions) plus paracentesis with paracentesis alone in 258 patients with symptomatic malignant ascites due to EpCAM-positive carcinomas. Median puncture-free survival, the primary endpoint, was significantly longer with catumaxomab than with drainage alone (46 days vs 11 days; p<0.0001). Median time to the next therapeutic puncture was also significantly increased in the catumaxomab group compared with the drainage-alone group (77 days versus 13 days; p<0.0001) and there was a trend towards increased overall survival with catumaxomab (72 days vs 68 days; p=0.0846).

View Removab drug record

Further Information: Fresenius Kabi

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases